Trials / Completed
CompletedNCT01397864
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
C1 Inhibitor Treatment Registry to Assess the Safety and Immunological Profile of Ruconest in the Treatment of HAE Attacks
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 181 (actual)
- Sponsor
- Pharming Technologies B.V. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (rhC1INH / Ruconest), to observe adverse events and insufficient efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest.
Detailed description
see below
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhC1INH or pdC1INH | C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest) |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2024-10-18
- Completion
- 2024-12-10
- First posted
- 2011-07-20
- Last updated
- 2025-04-08
Locations
17 sites across 13 countries: Bulgaria, Croatia, Czechia, France, Germany, Hungary, Italy, North Macedonia, Norway, Poland, Slovakia, Slovenia, Sweden
Source: ClinicalTrials.gov record NCT01397864. Inclusion in this directory is not an endorsement.